PDGFRB Cancer Research Results

PDGFRB, Platelet-derived growth factor receptor beta: Click to Expand ⟱
Source:
Type:

PDGFRB is a true druggable receptor tyrosine kinase with relevance to tumor stroma, angiogenesis, pericytes, fibrosis, BBB integrity, and AD vascular dysfunction.

Field Suggested Entry
Target PDGFRB / PDGFR-β
Full Name Platelet-derived growth factor receptor beta
Target Class Receptor tyrosine kinase
Main Ligands PDGF-BB, PDGF-DD
Primary Biology Pericyte recruitment, vascular maturation, fibroblast activation, stromal remodeling, cell migration, proliferation, BBB maintenance
Cancer Relevance High: tumor stroma, angiogenesis, pericytes, CAFs, invasion, metastasis, therapy resistance
AD Relevance Medium-high: brain pericytes, blood-brain barrier integrity, neurovascular dysfunction, soluble PDGFRβ as a pericyte injury marker
Therapeutic Direction Context-dependent. In cancer, inhibition or stromal normalization may be useful. In AD, preservation/restoration of PDGFRβ signaling is likely protective.


Scientific Papers found: Click to Expand⟱
6466- 1,8-Cin,    Transcriptome Analysis Reveals the Anti-Tumor Mechanism of Eucalyptol Treatment on Neuroblastoma Cell Line SH-SY5Y
- in-vitro, neuroblastoma, SH-SY5Y
AntiTum↑, Previous studies have shown that eucalyptol has anti-tumor effects on leukemia and colon cancer.
TumCCA↑, GO function analysis showed that positive regulation of cell cycle was down-regulated in biological processes.
PDGFRB↓, fig 2
Myc↓, BAD3, TBX3 and APC were up-regulated genes, at the same time, oncogenes LEF1, PDGFRB, and MYC were down-regulated genes
LEF1↓,
BAD↑,
APC↑,
TBX3↑,

7393- Amla,    Emblica officinalis extract induces autophagy and inhibits human ovarian cancer cell proliferation, angiogenesis, growth of mouse xenograft tumors
- vitro+vivo, Ovarian, OVCAR-3 - in-vitro, Ovarian, SW626
TumCP↓, Amla extract (AE) has anti-proliferative effects on OC cells under both in vitro and in vivo conditions.
Beclin-1/ATG6↑, AE did not induce apoptotic cell death, but did significantly increase the expression of the autophagic proteins beclin1 and LC3B-II under in vitro conditions.
LC3B-II↑,
Hif1a↓, AE also significantly reduced the expression of several angiogenic genes, including hypoxia-inducible factor 1α (HIF-1α) in OVCAR3 cells.
Dose↝, cell proliferation was significantly inhibited at AE concentrations ranging from 300–1000 µg/ml
TumAuto↑, AE induces autophagy in OVCAR3 and SW626 cells
angioG↓, AE inhibits angiogenesis-related genes in OVCAR3 cells
COL4A3↓, The expression of COL4A3, CXCL6, ECGF1, EFNB2, FGF2, IL1β, PDGFB, TNFRSF12A and HIF-1α were reduced to less than 40% of control levels (Figure 5D), with Hif-1α being inhibited to the greatest extent.
CXCL6/GCP-2↓,
TYMP/ECGF1↓,
IL1β↓,
PDGFRB↓,
ChemoSen↑, AE with cisplatin synergistically reduced cell proliferation in OVCAR3 cells
Dose↝, mice were fed orally with 10% sucrose (control) or 10% sucrose with AE (100 mg/kg body wt.) daily.

7565- HYP,    Potential Implications of Hyperoside on Oxidative Stress-Induced Human Diseases: A Comprehensive Review
- Review, AD, NA
*Inflam↓, exhibits a multitude of biological functions including anti-inflammatory, antidepressant, antioxidative, vascular protective effects and neuroprotective effects,
*antiOx↑,
*neuroP↑,
*lipid-P↓, Anti-oxidant Saccharomyces Cerevisiae 5, 20 mg/L Decreased LPO and the level of ROS
*ROS↓,
*IL1β↓, HT22 cells 20 μM Alleviates the level of IL-1β, IL-6, IL-8, TNF-α, ROS, MDA, Bax, and caspase-3; increases the expression of CAT, SOD, GSH, Bcl-2, BDNF, TrkB, and NGF.
*IL6↓,
*IL8↓,
*TNF-α↓,
*MDA↓,
*BAX↓,
*Casp3↓,
*Catalase↑,
*SOD↑,
*GSH↑,
*BDNF↑,
*TrkB↑,
*NGF↑,
*BDNF↑, Male Albino Swiss mice 0.94 mg/kg, 3.75 mg/kg Mediated by monoaminergic system and the upregulation of BDNF level
*NF-kB↓, Inhibited the activation of NF-κB, lessened the expression of iNOS,
*AChE↓, ICR mice 2.5 mg/kg Inhibited AchE activity
*H2S↑, SD rats 1, 10, 100 μM Upregulation of H2S,
Casp3↑, Anti-lung cancer A549 cells, Balb/c-nude mice 15, 20, 25 μM in vitro 15, 20, 25 mg/kg in vivo Activation of caspase-3 to motivate apoptosis and inactivation of NF-κB to inhibit inflammatory
Apoptosis↑,
NF-kB↓,
AMPK↑, A549 cells 10, 50, 100 μM Upregulation of AMPK signal pathway and HO-1 expression to suppressed the survival and proliferation of A549 cells
HO-1↑,
MAPK↑, A549 cells, H466 cells, C57BL/6J mice – Upregulated the expression of p38 MAPK, caspase 3, caspase 9, cleaved caspase 3, cleaved caspase 9 and Bax, downregulated the expression of Cu/Zn SOD, CAT, Nrf2, NQO1, HO-1 and Bcl-2
cl‑Casp3↑,
cl‑Casp9↑,
BAX↑,
SOD?,
Catalase↓,
NRF2↓,
NQO1↓,
HO-1↓,
Bcl-2↓,
TumCCA↑, A549 cells 10, 20, 50, 100, 200, 400 μg/mL Inhibited the process of G1/S phase to inhibit proliferation
FOXO1↑, NCI-H1975 cells, PC-9 cells, Nude male mice 30, 60, 90, 120, 150 μM in vitro, 25 mg/kg in vivo Upregulation of FoxO1
TumAuto↑, A549 cells 0.5, 1, 2 mM Induced autophagy through inhibiting the Akt/mTOR/p70S6K signal pathway
Akt↓,
mTOR↓,
P70S6K↓,
BMP7/OP1↓, HepG2 cells 5, 10, 20, 40, 80 μM Inhibiting the BMP-7
*cardioP↑, Cardiovascular Protective Effect
*hepatoP↑, Hepatoprotective
*antiCG↑, The report indicates hyperoside possesses antithrombotic activities and offer bases for development of a novel anticoagulant
*AntiThr↑,
*Diar↓, Antidiarrheal Activity
*AntiFungal↑, Antifungal Activity
*CYP2D6↓, hyperoside is a potent selective CYP2D6 inhibitor in HLMs, and might cause herb-drug interactions when co-administrated with CYP2D substrates.
*PDGFR-BB↓, In diabetic rats’ model, hyperoside inhibited the platelet-derived growth factor-BB (PDGF-BB)/platelet-derived growth factor-B receptor (PDGFR-β) ligand binding
*PDGFRB↓,
*toxicity↓, In research conducted in Wistar rats, the researchers demonstrated that in a long-term oral administration lasted for 6 months, hyperoside has a good safety. And the possible target organ of toxicity is kidney and the damage is reversible
*Half-Life↑, hyperoside also showed a long half-life for 4 hours and the safety experiments also proves that it has good safety.

7999- itraC,    Itraconazole-Induced Inhibition on Human Esophageal Cancer Cell Growth Requires AMPK Activation
- vitro+vivo, ESCC, NA
AMPK↑, AMPK activation by itraconazole induced multiple receptor tyrosine kinases (RTKs: EGFR, PDGFRα, and PDGFRβ), lysosomal translocation, and degradation to inhibit downstream Akt activation.
EGFR↓,
PDGFRA↓,
PDGFRB↓,
Akt↓,
TumCG↓, In vivo, itraconazole oral gavage potently inhibited Eca-109 tumor growth in SCID mice.


Showing Research Papers: 1 to 4 of 4

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 4

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

BMP7/OP1↓, 1,   COL4A3↓, 1,   CXCL6/GCP-2↓, 1,   TYMP/ECGF1↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

Catalase↓, 1,   HO-1↓, 1,   HO-1↑, 1,   NQO1↓, 1,   NRF2↓, 1,   SOD?, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

AMPK↑, 2,  

Cell Death(tgid=5) ⓘ

Akt↓, 2,   Apoptosis↑, 1,   BAD↑, 1,   BAX↑, 1,   Bcl-2↓, 1,   Casp3↑, 1,   cl‑Casp3↑, 1,   cl‑Casp9↑, 1,   MAPK↑, 1,   Myc↓, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

Beclin-1/ATG6↑, 1,   LC3B-II↑, 1,   TumAuto↑, 2,  

Cell Cycle & Senescence(tgid=11) ⓘ

TBX3↑, 1,   TumCCA↑, 2,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

FOXO1↑, 1,   mTOR↓, 1,   P70S6K↓, 1,   PDGFRA↓, 1,   PDGFRB↓, 3,   TumCG↓, 1,  

Migration(tgid=13) ⓘ

APC↑, 1,   LEF1↓, 1,   TumCP↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 1,   EGFR↓, 1,   Hif1a↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

IL1β↓, 1,   NF-kB↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ChemoSen↑, 1,   Dose↝, 2,  

Clinical Biomarkers(tgid=22) ⓘ

EGFR↓, 1,   Myc↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiTum↑, 1,  
Total Targets: 45

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

antiCG↑, 1,   CYP2D6↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   Catalase↑, 1,   GSH↑, 1,   lipid-P↓, 1,   MDA↓, 1,   ROS↓, 1,   SOD↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

H2S↑, 1,  

Cell Death(tgid=5) ⓘ

BAX↓, 1,   Casp3↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

AntiThr↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

PDGFRB↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

PDGFR-BB↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

IL1β↓, 1,   IL6↓, 1,   IL8↓, 1,   Inflam↓, 1,   NF-kB↓, 1,   TNF-α↓, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

AChE↓, 1,   BDNF↑, 2,   NGF↑, 1,   TrkB↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

Half-Life↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

IL6↓, 1,  

Functional Outcomes(tgid=23) ⓘ

cardioP↑, 1,   hepatoP↑, 1,   neuroP↑, 1,   toxicity↓, 1,  

Infection & Microbiome(tgid=24) ⓘ

AntiFungal↑, 1,   Diar↓, 1,  
Total Targets: 33

Scientific Paper Hit Count for: PDGFRB, Platelet-derived growth factor receptor beta
1 1,8-Cineole
1 Phyllanthus emblica/Emblica officinalis/Amla / Indian Gooseberry
1 Hyperoside
1 itraconazole
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:1495  State#:%  Dir#:1
  wNotes=on  sortOrder:rid,rpid

 

Home Page